A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease

Figure 3 ANG3070 attenuates renal pathology and fibrosis in the PCK rat. A, B and D: By week 14, kidney mass (A), kidney-to-body mass ratio (B) and renal cystic index (D) were several-fold higher in PCK [vehicle (Veh)] rats compared to the WT cohort (^bP < 0.01, vs WT). ANG3070 therapy from weeks 6-14, mitigated renomegaly (A and B); C: Representative H and E-stained renal transverse sections from PCK + Veh and a PCK + ANG3070 rats demonstrating cystic distribution across the renal parenchyma at week 14; D: Treatment with ANG3070 reduced renal cystic index (^dP < 0.01, vs PCK + veh); E: Representative Masson’s trichrome stained renal sections from PCK rats showing scarring within the renal interstitium (arrows) of PCK rats; F: Total kidney hydroxyproline (HYP-a marker of collagen) content was increased at week 14 in the PCK (Veh) rat (^bP < 0.01, vs WT). Treatment with ANG3070 was associated with a reduction in HYP, marker of kidney fibrosis (^dP < 0.01, vs PCK + Veh).